---
layout: post
title: "Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments; Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability"
date: 2026-02-04 21:46:42 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-20153
original_published: 2025-11-18 00:00:00 +0000
significance: 8.00
---

# Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments; Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders; Availability

**Published:** February 04, 2026 21:46 UTC
**Source:** Federal Register
**Original Published:** November 18, 2025 00:00 UTC
**Document Number:** 2025-20153

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry, FDA staff, and other stakeholders entitled "Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments." This guidance (Guidance 3) is the third in a series of four methodological patient-focused drug development (PFDD) guidance documents that describe how stakeholders (patients, researchers, medical product developers, and others) can submit patient experience and other relevant information from patients and caregivers to be used for medical product development and regulatory decision-making. This guidance finalizes the draft guidance of the same title issued on June 30, 2022.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/11/18/2025-20153/patient-focused-drug-development-selecting-developing-or-modifying-fit-for-purpose-clinical-outcome)
- API: https://www.federalregister.gov/api/v1/documents/2025-20153

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
